(“Fortress” or “the Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as Fortress Companies. The Company will leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals. Additionally, the Company will provide funding and management services to each of the Fortress Companies and from time to time the Company and the Fortress Companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
Companies To Watch
XXII 1.39 +0.01 CKPT 10.25 +0.00 CPHR 2.9901 +0.0000 CFRX 1.40 -0.10 CRBP 6.45 -0.30 DMPI 2.20 -0.10 DVAX 5.70 +0.15 FBIO 3.95 +0.11 KERX 6.46 +0.04 MTNB 3.00 -0.03 MDGN 5.57 +0.17 MNOV 5.95 -0.10 MTFB 8.99 +0.59 PRQR 5.00 +0.05 STML 8.45 +0.10 SYN 0.6068 +0.0148 TGTX 12.05 +0.15 THLD 0.4693 +0.0093 TNXP 4.46 +0.11 VSTM 2.37 +0.00 ZIOP 6.29 -0.28 2017-05-26 16:01
- Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
- Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
- Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol